P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Update

P3 Health Partners Inc. (NASDAQ:PIII) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 68,522 shares, a decline of 50.4% from the May 31st total of 138,133 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 103,356 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On P3 Health Partners

An institutional investor recently bought a new position in P3 Health Partners stock. Lido Advisors LLC purchased a new position in P3 Health Partners Inc. (NASDAQ:PIII) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners at the end of the most recent reporting period. 7.75% of the stock is currently owned by hedge funds and other institutional investors.

P3 Health Partners Price Performance

Shares of NASDAQ PIII traded down $0.62 during trading on Tuesday, hitting $11.32. 14,350 shares of the company were exchanged, compared to its average volume of 692,589. The company has a market cap of $81.96 million, a price-to-earnings ratio of -0.29 and a beta of 1.57. P3 Health Partners has a 1 year low of $1.52 and a 1 year high of $16.89. The firm’s fifty day moving average price is $8.81 and its 200 day moving average price is $4.98.

P3 Health Partners (NASDAQ:PIII) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.85) by $5.17. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%. The business had revenue of $386.39 million during the quarter, compared to the consensus estimate of $391.45 million.

Analyst Ratings Changes

PIII has been the subject of several analyst reports. TD Cowen reissued a “hold” rating and set a $14.00 price target (up from $3.00) on shares of P3 Health Partners in a report on Friday, May 22nd. Weiss Ratings raised P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. UBS Group set a $14.00 target price on P3 Health Partners in a research report on Friday, May 15th. Finally, Lake Street Capital reissued a “buy” rating and set a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $14.00.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.